Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

IASLC: Taletrectinib in ROS1-Positive NSCLC

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

NeoCOAST 2 Trial Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC

FDA Seeks Consumer Representatives for ODAC

Using TROP2 Expression to Predict Outcomes in Advanced NSCLC